Janus Kinase Inhibitor Market Demands and Growth Prediction till 2026
Janus Kinase Inhibitor Market – Size, Share, Outlook, and Opportunity Analysis 2018 - 2026
Janus Kinase Inhibitor Market Drivers
Jak inhibitors are increasingly preferred for industrial research due to their critical role in immune response signaling. For instance, in June 2018, Eli Lilly and Company announced approval from the U.S. Food and Drug Administration (FDA) for OLUMIANT (baricitinib)
To Have A Snippet Of The Report, Request Sample: https://www.coherentmarketinsights.com/
Psoriatic arthritis is a form of arthritis, which is characterized by red patches of skin with silvery scales. Tofacitinib is a janus kinase inhibitor, which modulates cytokines that are required for signaling of inflammatory and immune response. Inclusion of new treatment options is expected to boost the global janus kinase inhibitor market growth over the forecast period. For instance, in December 2017, Pfizer Inc. received approval from the U.S. FDA for XELJANZ (TOFACITINIB)
Janus Kinase Inhibitor Market Regional Analysis
The Janus kinase pathway mediates intracellular signaling of over sixty cytokines. Dysregulation of cytokines causes systemic lupus erythematosus (SLE) -- an autoimmune disorder and chronic disease, which is characterized by inflammation of connective tissues such as cartilage and blood vessel lining. According to National Center for Biotechnology Information (NCBI), the highest prevalence and incidence of SLE was in recorded in North America (23.2/100 000 person) during the period August 2013- September 2016. Therefore, high prevalence of SLE is expected to boost North America janus kinase inhibitor market growth over the forecast period.
Janus Kinase Inhibitor Market Key Players
Some of the key players operating in the global Janus kinase inhibitor market include, Eli Lilly and Company, Astellas Pharma Inc., Pfizer Inc., Baxter International Inc., Novartis International AG, Gilead Sciences Inc., Sierra Oncology, Inc., CTI BioPharma Corp., and Incyte Corporation.
Janus Kinase Inhibitor Market Taxonomy
The global janus kinase inhibitor market is segmented on the basis of drugs, indication, distribution channel and regions.
• Pipeline drugs
• Rheumatoid arthritis
• Psoriatic arthritis
• Systemic lupus erythematosus
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154